Table I.

Clinical studies evaluating repeated intravenous infusions of a pathotropic Mx-dnG1 retrovector (Rexin-G) as monotherapy for chemoresistant metastatic cancer.

Completed studies	Types of cancer treated	Description of results, conclusions	(Refs.)
International phase I/II protocols for pancreatic cancer are expanded to include all solid tumors	Advanced pancreatic cancer, expanded to include metastatic melanoma, breast, uterus, colon cancer, and leiomyosarcoma	Demonstrations of overall safety, lack of toxicity, and potential for clinical efficacy is established; a dose-response calculus is advanced	(90,91)
Phase I (USA) low-dose safety study in advanced or metastatic pancreatic Ca	Advanced pancreatic cancer	General safety is confirmed; no RCR no inactivating antibodies; no DLT, enabled further dose escalation(s)	(92)
Phase I/II dose escalation studies of safety and efficacy	Chemotherapy-resistant sarcoma, breast cancer and pancreatic cancer	Demonstrates significant anticancer activity (efficacy) without toxicity	(93,94)
Phase I/II with advanced phase II study of resistant sarcoma and osteosarcoma	Chemotherapy-resistant sarcoma and osteosarcoma	Safety and dose-dependent clinical efficacy is demonstrated; significant improvements in overall survival	(95,96)
Advanced phase I/II study of chemotherapy-resistant metastatic pancreatic Ca	Advanced pancreatic cancer	Safety and dose-dependent clinical efficacy is demonstrated; significant improvements in overall survival	(97)